The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder: A Randomized, Double-Blind Comparison With Sertraline
Abstract
OBJECTIVE: This study evaluates the efficacy of agomelatine, the first antidepressant to be an agonist at MT(1)/MT(2) receptors and an antagonist at 5-HT(2C) receptors, versus sertraline with regard to the amplitude of the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder (MDD). METHOD: Outpatients with DSM-IV-TR-defined MDD received either agomelatine 25 to 50 mg (n = 154) or sertraline 50 to 100 mg (n = 159) during a 6-week, randomized, double-blind treatment period. The study was conducted from 2005 to 2006. The main outcome measure was the relative amplitude of the individual rest-activity cycles, expressed as change from baseline to week 6 and collected from continuous records using wrist actigraphy and sleep logs. Secondary outcome measures were sleep efficiency and sleep latency, both derived from actigraphy, and efficacy on depression symptoms (17-Item Hamilton Depression Rating Scale total score and Clinical Global Impressions scale scores) and anxiety symptoms (Hamilton Anxiety Rating Scale total score and subscores). RESULTS: A significant difference in favor of agomelatine compared to sertraline on the relative amplitude of the circadian rest-activity cycle was observed at the end of the first week (P = .01). In parallel, a significant improvement of sleep latency (P <.001) and sleep efficiency (P <.001) from week 1 to week 6 was observed with agomelatine as compared to sertraline. Over the 6-week treatment period, depressive symptoms improved significantly more with agomelatine than with sertraline (P <.05), as did anxiety symptoms (P <.05). CONCLUSIONS: The favorable effect of agomelatine on the relative amplitude of the circadian rest-activity/sleep-wake cycle in depressed patients at week 1 reflects early improvement in sleep and daytime functioning. Higher efficacy results were observed with agomelatine as compared to sertraline on both depressive and anxiety symptoms over the 6-week treatment period, together with a good tolerability profile. These findings indicate that agomelatine offers promising benefits for MDD patients. TRIAL REGISTRATION: www.isrctn.org: ISRCTN49376288.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
(1976) · Medical Entomology and Zoology · Cited by 8,899
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
The Role of Actigraphy in the Study of Sleep and Circadian Rhythms
Ancoli-Israel, S., Cole, R., Alessi, C., Chambers, M., Moorcroft, W., & Pollak, C. P. (2003) · Sleep · doi:10.1093/sleep/26.3.342 · Cited by 2,751 · cited 1×
“The miniaturized wrist-worn devices used in this study allowed ambulatory measurements for several weeks in the patient’s natural environment with minimal interference in the everyday lifestyle.(32) In sleep research and chronobiology, actigraphy has proved useful as a method to indirectly measure sleep and characteri…”
MethodSheehan, D., Lecrubier, Y., Harnett Sheehan, K., Janavs, J., Weiller, E., Keskiner, A., Schinka, J., Knapp, E., Sheehan, M., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83297-x · Cited by 2,149
The Role of Actigraphy in the Evaluation of Sleep Disorders
Sadeh, A., Hauri, P. J., Kripke, D. F., & Lavie, P. (1995) · Sleep · doi:10.1093/sleep/18.4.288 · Cited by 909
Circadian rhythm disturbances in depression
Germain, A., & Kupfer, D. J. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.964 · Cited by 644
Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Millan, M. J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J.-M., & Cussac, D. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051797 · Cited by 516
Cited by
Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease
Wulff, K., Gatti, S., Wettstein, J. G., & Foster, R. G. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2868 · Cited by 1,055
Self-citationAgomelatine, the first melatonergic antidepressant: discovery, characterization and development
de Bodinat, C., Guardiola-Lemaitre, B., Mocaër, E., Renard, P., Muñoz, C., & Millan, M. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3140 · Cited by 593
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
Melatonin and its analogs in insomnia and depression
Cardinali, D. P., Srinivasan, V., Brzezinski, A., & Brown, G. M. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00962.x · Cited by 353
Novel melatonin-based therapies: potential advances in the treatment of major depression
Hickie, I. B., & Rogers, N. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60095-0 · Cited by 334
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
Taylor, D., Sparshatt, A., Varma, S., & Olofinjana, O. (2014) · BMJ · doi:10.1136/bmj.g1888 · Cited by 334
Mode of action of agomelatine: Synergy between melatonergic and 5-HT2Creceptors
Racagni, G., Riva, M. A., Molteni, R., Musazzi, L., Calabrese, F., Popoli, M., & Tardito, D. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.595823 · Cited by 282
Crouse, J. J., Carpenter, J. S., Song, Y. J. C., Hockey, S. J., Naismith, S. L., Grunstein, R. R., Scott, E. M., Merikangas, K. R., Scott, J., & Hickie, I. B. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00034-1 · Cited by 255
Antidepressant therapies inhibit inflammation and microglial M1-polarization
Kalkman, H. O., & Feuerbach, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.001 · Cited by 212
Guardiola‐Lemaitre, B., De Bodinat, C., Delagrange, P., Millan, M. J., Munoz, C., & Mocaër, E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12720 · Cited by 182
Circadian rhythms and depression: Human psychopathology and animal models
Kronfeld-Schor, N., & Einat, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.020 · Cited by 166
Links between circadian rhythms and psychiatric disease
Karatsoreos, I. N. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00162 · Cited by 146
Montgomery, S. A., Nielsen, R. Z., Poulsen, L. H., & Häggström, L. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2424 · Cited by 143
“, 2010), sertraline (Kasper et al., 2010) and venlafaxine (Lemoine et al.”
BackgroundActigraphy for evaluation of mood disorders: A systematic review and meta-analysis
Tazawa, Y., Wada, M., Mitsukura, Y., Takamiya, A., Kitazawa, M., Yoshimura, M., Mimura, M., & Kishimoto, T. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.087 · Cited by 115
Circadian depression: A mood disorder phenotype
Carpenter, J. S., Crouse, J. J., Scott, E. M., Naismith, S. L., Wilson, C., Scott, J., Merikangas, K. R., & Hickie, I. B. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.045 · Cited by 114
Circadian Rhythms, Melatonin and Depression
A. Quera Salva, M., Hartley, S., Barbot, F., C. Alvarez, J., Lofaso, F., & Guilleminault, C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796197188 · Cited by 100
Corruble, E., de Bodinat, C., Belaïdi, C., & Goodwin, G. M. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000679 · Cited by 94
“The antidepressant efficacy of both drugs was high, confirming previous findings obtained at the same 24-wk time-point with agomelatine and escitalopram in MDD patients (Colonna et al., 2005; Kennedy and Rizvi, 2010).”
ResultDuncan, W. C., Slonena, E., Hejazi, N. S., Brutsche, N., Yu, K. C., Park, L., Ballard, E. D., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.011 · Cited by 93
“For example, activity patterns are ph ase-advanced after SD (28) and bright light (12) therapies, and altered 24-hour amplitude is of ten associated with increased day and decreased night activity following treatment interv entions (12, 29-32).”
Role of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
Agomelatine in Generalized Anxiety Disorder: An Active Comparator and Placebo-Controlled Study
Stein, D. J., Ahokas, A., Márquez, M. S., Höschl, C., Oh, K. S., Jarema, M., Avedisova, A. S., Albarran, C., & Olivier, V. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08433 · Cited by 67
Fornaro, M., McCarthy, M. J., De Berardis, D., Pasquale, D., Martino, Colicchio, Cattaneo, D'Angelo, Fornaro, P., & Tabaton (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41557 · Cited by 67
Tchekalarova, J., Stoynova, T., Ilieva, K., Mitreva, R., & Atanasova, M. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.05.016 · Cited by 67
Duncan, W. C., Ballard, E. D., & Zarate, C. A. (2017) · Handbook of Experimental Pharmacology · doi:10.1007/164_2017_51 · Cited by 58
Robillard, R., Carpenter, J. S., Feilds, K.-L., Hermens, D. F., White, D., Naismith, S. L., Bartlett, D., Whitwell, B., Southan, J., Scott, E. M., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00624 · Cited by 51
Smagula, S. F. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000283 · Cited by 47
Koresh, O., Kozlovsky, N., Kaplan, Z., Zohar, J., Matar, M. A., & Cohen, H. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.012 · Cited by 40
Melatonin and agomelatine for preventing seasonal affective disorder
Kaminski-Hartenthaler, A., Nussbaumer, B., Forneris, C. A., Morgan, L. C., Gaynes, B. N., Sonis, J. H., Greenblatt, A., Wipplinger, J., Lux, L. J., Winkler, D., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011271.pub2 · Cited by 39
Pain management in people with severe mental illness: an agenda for progress
Onwumere, J., Stubbs, B., Stirling, M., Shiers, D., Gaughran, F., Rice, A. S. C., C de C Williams, A., & Scott, W. (2022) · Pain · doi:10.1097/j.pain.0000000000002633 · Cited by 35
Brignone, M., Diamand, F., Painchault, C., & Takyar, S. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1128404 · Cited by 30
Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
Levitan, M., Papelbaum, M., & E Nardi, A. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s67470 · Cited by 25
Actigraphy in patients with treatment-resistant depression undergoing electroconvulsive therapy
Winkler, D., Pjrek, E., Lanzenberger, R., Baldinger, P., Eitel, D., Kasper, S., & Frey, R. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.06.006 · Cited by 21
Self-citationNishida, M., Kikuchi, S., Nisijima, K., & Suda, S. (2017) · The Journal of ECT · doi:10.1097/yct.0000000000000352 · Cited by 19
Are 24-hour motor activity patterns associated with continued rapid response to ketamine?
Duncan Jr, W. C., Slonena, E. E., Hejazi, N. S., Brutsche, N., Park, L. T., Henter, I. D., Ballard, E. D., & Zarate Jr, C. A. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s172089 · Cited by 17
Metadata
- Authors
- Kasper, S., Hajak, G., Wulff, K., Hoogendijk, W. J. G., Montejo, A. L., Smeraldi, E., Rybakowski, J. K., Quera-Salva, M.-A., Wirz-Justice, A. M., Picarel-Blanchot, F., & Baylé, F. J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-02-15
- Volume
- 71
- Issue
- 02
- Pages
- 109-120
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2086546977
- Cited by
- 257
- References
- 50
- FWCI
- 22.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.